2024-09-25 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis:

**1. Performance Comparison:**

Amgen Inc. (AMGN) has a cumulative return of 86.7% compared to the S&P 500 (VOO) with a return of 133.37%. This puts AMGN at a **-46.67%** difference compared to the S&P 500, which is **39.18%** of the maximum historical difference. 

**Company Overview:** Amgen is a leading biotechnology company developing, manufacturing, and delivering innovative human therapeutics in various therapeutic areas.

**2. Recent Price Movement:**

* **Closing Price:** $333.17
* **5-day Moving Average:** $335.03
* **20-day Moving Average:** $330.85
* **60-day Moving Average:** $327.66

The recent price action shows a slight downward trend, with the closing price below all three moving averages.

**3. Technical Indicators:**

* **RSI:** 53.37: This indicates a neutral market sentiment, with the stock neither overbought nor oversold.
* **PPO:** 0.13: A positive PPO suggests bullish momentum, but a relatively low value may indicate a weakening trend.
* **Delta_Previous_Relative_Divergence:** -0.81: This negative value indicates a recent **short-term downward trend** in the stock's relative performance compared to the market.
* **Expected Return:** 0.0%: This represents a 5-year projected return for a potential investment, currently at 0%.

**4. Recent Earnings and Outlook:**

| Date       | EPS | Revenue |
|------------|-----|---------|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

The most recent earnings report (2024-08-07) showed an EPS of 1.39 and revenue of $8.39 billion. This surpassed analysts' expectations of EPS 1.23 and revenue $8.19 billion. The positive beat indicates strong growth and a positive outlook for the company.

**5. News and Recent Issues:**

Recent market outlook for AMGN is positive. Analysts highlight strong earnings and robust product pipeline as key factors for future growth. 

**Analyst Opinions:**

* **FINBOLD:**  "Amgen's stock has been a strong performer in recent years, and analysts are bullish on the company's prospects. Amgen has a strong product pipeline and is well-positioned to benefit from the growing demand for biopharmaceuticals." 
* **Other analysts:**  Overall, analysts have a positive outlook on AMGN, with many projecting significant growth potential in the upcoming years.

**6. Summary:**

Amgen Inc. (AMGN) is a well-established biotechnology company with a strong product portfolio and a positive market outlook. While the stock has underperformed the S&P 500 recently, strong earnings and a robust pipeline suggest potential for growth.  Technical indicators point to a neutral market sentiment, with some signs of a short-term downward trend. Overall, AMGN remains a promising investment for investors seeking exposure to the biotechnology sector. 

**7. Report (English):**

This report provides a comprehensive analysis of Amgen Inc. (AMGN) stock, covering key aspects including performance comparison, recent price movement, technical indicators, recent earnings and outlook, and news and recent issues. 

**Key findings:**

* AMGN has underperformed the S&P 500 in recent years.
* The stock exhibits a slight downward trend, but recent earnings have surpassed analyst expectations.
* Technical indicators suggest a neutral market sentiment, but some signs of a short-term downward trend.
* Analyst opinions remain positive, highlighting strong earnings, a robust pipeline, and future growth potential.

**Overall, AMGN remains a promising investment for investors seeking exposure to the biotechnology sector. However, considering the recent underperformance and short-term downtrend, investors should monitor the stock closely for further developments.**